AP-002

AP-002 caused these inhibitory effects without causing osteoclast cell death, which was in contrast to zoledronic acid controls. AP-002 promotes osteogenesis in this therapeutic window, while blocking osteoclast development. We therefore conclude that AP-002 has potential as a new anti-bone resorption agent, with a mechanism of action different compared with other currently marketed anti-bone resorption agents.